{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:16:11Z","timestamp":1778634971779,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004700","name":"Taipei Medical University","doi-asserted-by":"publisher","award":["N202505053"],"award-info":[{"award-number":["N202505053"]}],"id":[{"id":"10.13039\/501100004700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014134","name":"Trust for Mutual Understanding","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014134","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022600","name":"Wan Fang Hospital","doi-asserted-by":"publisher","award":["113-wf-phd-01"],"award-info":[{"award-number":["113-wf-phd-01"]}],"id":[{"id":"10.13039\/501100022600","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.mayocp.2025.08.024","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T04:22:55Z","timestamp":1764908575000},"page":"38-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Influence of Metabolic Factor Control on Psoriatic Arthritis Risk in Psoriasis Patients"],"prefix":"10.1016","volume":"101","author":[{"given":"Yi-Hsuan","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Chen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9364","key":"10.1016\/j.mayocp.2025.08.024_bib1","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/S0140-6736(03)12954-6","article-title":"Psoriasis","volume":"361","author":"Lebwohl","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.024_bib2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40744-016-0029-z","article-title":"Psoriatic arthritis and burden of disease: patient perspectives from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey","volume":"3","author":"Kavanaugh","year":"2016","journal-title":"Rheumatol Ther"},{"issue":"6","key":"10.1016\/j.mayocp.2025.08.024_bib3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11926-020-00891-x","article-title":"From psoriasis to psoriatic arthritis: insights from imaging on the transition to psoriatic arthritis and implications for arthritis prevention","volume":"22","author":"Zabotti","year":"2020","journal-title":"Curr Rheumatol Rep"},{"issue":"9","key":"10.1016\/j.mayocp.2025.08.024_bib4","first-page":"1856","article-title":"Risk factors for psoriatic arthritis development in psoriasis patients: myths, pitfalls, and pearls","volume":"42","author":"Patt","year":"2024","journal-title":"Clin Exp Rheumatol"},{"issue":"suppl 2","key":"10.1016\/j.mayocp.2025.08.024_bib5","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","volume":"64 Suppl 2","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.mayocp.2025.08.024_bib6","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/jid.2010.103","article-title":"Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions","volume":"130","author":"Davidovici","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.1016\/j.mayocp.2025.08.024_bib7","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S2213-8587(18)30127-X","article-title":"Psoriasis: a novel risk factor for type 2 diabetes","volume":"6","author":"Gelfand","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.mayocp.2025.08.024_bib8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/CLEP.S346128","article-title":"The risk of gout in patients with psoriasis: a population-based cohort study in Taiwan","volume":"14","author":"Wei","year":"2022","journal-title":"Clin Epidemiol"},{"issue":"6","key":"10.1016\/j.mayocp.2025.08.024_bib9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2340\/00015555-0510","article-title":"Psoriasis and dyslipidaemia: a population-based study","volume":"88","author":"Dreiher","year":"2008","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.024_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jaad.2013.09.005","article-title":"Hyperuricemia in patients with chronic plaque psoriasis","volume":"70","author":"Gisondi","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"13","key":"10.1016\/j.mayocp.2025.08.024_bib11","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.jacc.2021.02.009","article-title":"Cardiovascular risk in patients with psoriasis: JACC Review Topic of the Week","volume":"77","author":"Garshick","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.mayocp.2025.08.024_bib14","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1136\/annrheumdis-2021-220439","article-title":"Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan","volume":"80","author":"Koto","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.024_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clindermatol.2017.09.005","article-title":"Psoriasis and the metabolic syndrome","volume":"36","author":"Gisondi","year":"2018","journal-title":"Clin Dermatol"},{"issue":"25","key":"10.1016\/j.mayocp.2025.08.024_bib16","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.mayocp.2025.08.024_bib17","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/jdv.18044","article-title":"Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis","volume":"36","author":"Wu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.024_bib18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jaad.2011.06.035","article-title":"Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis","volume":"67","author":"Kimball","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.mayocp.2025.08.024_bib19","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1111\/jdv.14951","article-title":"Anti-inflammatory therapy with tumour necrosis factor inhibitors is associated with reduced risk of major adverse cardiovascular events in psoriasis","volume":"32","author":"Wu","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.mayocp.2025.08.024_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1354593","article-title":"Effects of tumor necrosis factor-alpha inhibitors on lipid profiles in patients with psoriasis: a systematic review and meta-analysis","volume":"15","author":"Su","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.mayocp.2025.08.024_bib21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jacl.2011.02.001","article-title":"Clinical implications of discordance between low-density lipoprotein cholesterol and particle number","volume":"5","author":"Otvos","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.mayocp.2025.08.024_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105057","article-title":"Effect of statin use on cardiovascular events and all-cause mortality in immune-mediated inflammatory diseases: a systematic review and meta-analysis involving 148,722 participants","volume":"160","author":"Xie","year":"2020","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.mayocp.2025.08.024_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2019.90343","article-title":"The effect of statins on psoriasis severity: a meta-analysis of randomized clinical trials","volume":"16","author":"Socha","year":"2020","journal-title":"Arch Med Sci"},{"issue":"2","key":"10.1016\/j.mayocp.2025.08.024_bib24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/BOR.0000000000000028","article-title":"Definition of hyperuricemia and gouty conditions","volume":"26","author":"Bardin","year":"2014","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"10.1016\/j.mayocp.2025.08.024_bib25","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","article-title":"Purine-rich foods, dairy and protein intake, and the risk of gout in men","volume":"350","author":"Choi","year":"2004","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocp.2025.08.024_bib26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2230.2010.03988.x","article-title":"Cross-sectional study on the correlation of serum uric acid with disease severity in Korean patients with psoriasis","volume":"36","author":"Kwon","year":"2011","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.mayocp.2025.08.024_bib27","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/jdv.15290","article-title":"Association between psoriasis, psoriatic arthritis and gout: a nationwide population-based study","volume":"33","author":"Hu","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.mayocp.2025.08.024_bib28","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/1346-8138.13968","article-title":"Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients","volume":"44","author":"Tsuruta","year":"2017","journal-title":"J Dermatol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619625005166?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619625005166?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:57:33Z","timestamp":1778633853000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619625005166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0025619625005166"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.08.024","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of Metabolic Factor Control on Psoriatic Arthritis Risk in Psoriasis Patients","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}